CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?
Amey Dhopeshwarkar(Northeastern University), Ken Mackie(Indiana University Bloomington)
Cited by 257
Related Papers
JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB<sub>1</sub>receptor agonist
|British Journal of Pharmacology|2010|260
Parsing the players: 2‐arachidonoylglycerol synthesis and degradation in the<scp>CNS</scp>
|British Journal of Pharmacology|2013|251
Functional Selectivity in CB2 Cannabinoid Receptor Signaling and Regulation: Implications for the Therapeutic Potential of CB2 Ligands
|Molecular Pharmacology|2011|152
Monoacylglycerol Lipase Limits the Duration of Endocannabinoid-Mediated Depolarization-Induced Suppression of Excitation in Autaptic Hippocampal Neurons
|Molecular Pharmacology|2009|96
Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists
|Journal of Pharmacology and Experimental Therapeutics|2016|26